November 16, 2020

IBRI RESEARCH PUBLISHED: Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological a-Synuclein in Parkinson’s Disease Patients

Abstract An assay for accurately diagnosing early stage Parkinson’s Disease (PD) is currently unavailable, and therefore, there is an urgent and unmet need. Such a diagnostic assay will enable...

November 12, 2020

IBRI IN THE NEWS: Biosciences Research Institute Adds Board Members

The Indiana Biosciences Research Institute has added eight members to its board of directors, including Bob Bernhard (pictured) and Wendy Srnic (pictured). Bernhard serves as vice president for research at...

November 11, 2020

IBRI RESEARCH PUBLISHED: YIPF5 Mutations Cause Neonatal Diabetes and Microcephaly through Endoplasmic Reticulum Stress

Abstract Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. Understanding the genetic basis of rare diabetes subtypes highlights fundamental...

November 09, 2020

Indiana Biosciences Research Institute Names New Board Members

Indianapolis, Ind. – The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce the addition of eight members to its Board of Directors. Its...

November 02, 2020

IBRI IN THE NEWS: The Dialogue of Diabetes

Over the past 60 years, the incidence of type I diabetes in parts of the word has increased sixfold, and we don’t know why. In the Eizirik Lab at the...

October 26, 2020

IBRI RESEARCH PUBLISHED: Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities

Abstact Background : Diabetes is a complex, multi-symptomatic disease whose complications drives increases in healthcare costs as the diabetes prevalence grows rapidly world-wide. Real-world electronic health records (EHRs) coupled...

October 20, 2020

IBRI RESEARCH PUBLISHED: SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic ß-cells and in the human pancreas microvasculature

Abstract Increasing evidence demonstrated that the expression of Angiotensin I-Converting Enzyme type 2 (ACE2), is a necessary step for SARS-CoV-2 infection permissiveness. In the light of the recent data...

October 01, 2020

IBRI RESEARCH PUBLISHED: Beta Cell Imaging—From Pre-Clinical Validation to First in Man Testing

Abstract There are presently no reliable ways to quantify human pancreatic beta cell mass (BCM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in...

September 18, 2020

IBRI IN THE NEWS: New Chief Wants to Grow IBRI's Global Reputation

Indianapolis - The new chief executive officer of the Indiana Biosciences Research Institute in Indianapolis says he wants to see the institute emerge as a global leader of innovative science...

September 15, 2020

IBRI RESEARCH PUBLISHED: Molecular Footprints of the Immune Assault on Pancreatic Beta Cells in Type 1 Diabetes

Abstract Type 1 diabetes (T1D) is a chronic disease caused by the selective destruction of the insulin-producing pancreatic beta cells by infiltrating immune cells. We presently evaluated the transcriptomic...

 1 2 3 4 5  ... Last 
2019 Annual Report cover

The IBRI 2019 Annual Report is now available. The report theme is “Catalyze, Complement, Connect,” which correlates with the IBRI's goals to seek solutions for health problems, enhance the Indiana life sciences ecosystem, and expedite solutions for the most pressing health issues.